Bristol Myers Sqibb News (NYSE:BMY)

DateTimeSource
Headline
06/24/201710:00AMBWFour-Year Follow-up with Empliciti (elotuzumab) Plus Lenalidomide/Dexamethasone (ELd) in Patients with Advanced Multiple Myel...
Combination therapy demonstrated a sustained reduction in risk of progression/death of 29% and relative improvement of 50% in progression-free survival rate of ELd (21%) compared to Ld alone (14%) The extended follow-up data is the longest of an Immuno-Oncology agent in relapsed/refractory multiple myeloma The data showed... More...>>
06/23/20177:29AMDJNOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a Cure
By Anne Steele The next frontier for multibillion-dollar drug therapies is a silent disease many people don't know they have. Dozens of pharmaceutical companies including Gilead Sciences Inc., Allergan PLC and Intercept Pharmaceuticals Inc. have joined the fray to bring a treatment for nonalcoholic steatohepatitis... More...>>
06/21/201710:00AMPRNUSS&P 500 Buybacks Fall 17.5% Year-over-Year to $133.1 Billion for Q1 2017
S&P 500 Buybacks Fall 17.5% Year-over-Year to $133.1 Billion for Q1 2017 - Q1 2017 repurchases is 1.6% less than Q4 2016 and 17.5% less than Q1 2016 - EPS support via share count reduction significantly declines - Cash reserves set new record PR Newswire NEW YORK, June 21, 2017 NEW YORK, June 21, 2017 /PRNewswire/... More...>>
06/21/20176:59AMBWBristol-Myers Squibb Announces the Expiration of its Cash Tender Offer
Bristol-Myers Squibb Company (NYSE:BMY) announced today the expiration, as of 5:00 p.m., New York City time, on June 20, 2017, of its previously announced cash tender offer for any and all of certain of its outstanding debt securities. Approximately $337.0 million in aggregate principal amount of the notes subject to the... More...>>
06/20/20173:40PMBWBristol-Myers Squibb Announces the Pricing Terms of its Cash Tender Offer For Any & All of Certain of its Outstanding Debt Se...
Bristol-Myers Squibb Company (NYSE:BMY) announced today the pricing terms of its previously announced cash tender offer for any and all of certain of its outstanding debt securities. The consideration for each series of notes is based on the applicable reference yield plus a fixed spread, in each case as set forth in the... More...>>
06/20/20173:02AMDJNDrug Suits Suffer Setback -- WSJ
By Jess Bravin WASHINGTON -- The Supreme Court on Monday dealt a blow to consumer plaintiffs by limiting where lawsuits against companies with business in multiple states can be heard. By an 8-1 vote, the court said California courts could hear only claims by Californians against Bristol-Myers Squibb Co., whose blood thinner... More...>>
06/19/20178:11PMDJNSupreme Court Further Curbs Plaintiffs' Venue Shopping With Bristol-Myers Ruling -- Update
By Jess Bravin WASHINGTON -- The Supreme Court on Monday dealt a blow to consumer plaintiffs by limiting where lawsuits against companies with business in multiple states can be heard. By an 8-1 vote, the court said California courts could hear only claims by Californians against Bristol-Myers Squibb Co., whose blood thinner... More...>>
06/19/20177:32PMDJNSupreme Court Further Curbs Plaintiffs' Venue Shopping With Bristol-Myers Ruling
By Jess Bravin WASHINGTON -- The Supreme Court on Monday dealt a blow to consumer plaintiffs by limiting where lawsuits against companies with business in multiple states can be heard. By an 8-1 vote, the court said California courts could hear only claims by Californians against Bristol-Myers Squibb Co., whose blood thinner... More...>>
06/16/20176:58AMBWExtended Follow-Up Data Evaluating Opdivo (nivolumab) Shows Durable Response in Adult Patients with Relapsed or Progressed...
Results show overall response rates of 65% or greater with median follow-up of at least 16 months, regardless of prior brentuximab vedotin therapies Bristol-Myers Squibb Company (NYSE:BMY) today announced extended follow-up data in which Opdivo (nivolumab) demonstrated responses in adult patients with relapsed or progressed... More...>>
06/16/20174:35AMBWBristol-Myers Squibb to Sell Manufacturing Facility in Swords, Ireland to SK Biotek Co., Ltd.
SK Biotek is first Korean company to invest in pharmaceutical manufacturing in Ireland and anticipates further investment by adding R&D, marketing and additional manufacturing capabilities Bristol-Myers Squibb shifts manufacturing focus in Ireland to reflect growing biologics portfolio with ongoing investment in Cruiserath... More...>>
06/15/20176:58AMBWSeattle Genetics & Bristol-Myers Squibb Highlight Interim Phase 1/2 Data Evaluating Combination of ADCETRIS® (Brentuximab Ve...
-Combination Data Show 85 Percent Objective Response Rate and 63 Percent Complete Response Rate with an Acceptable Safety Profile in these Pre-Transplant Relapsed or Refractory Classical Hodgkin Lymphoma Patients- -Data Support Recently Initiated Pivotal Phase 3 Clinical Trial Evaluating ADCETRIS and Opdivo Combination... More...>>
06/14/20178:40AMBWBristol-Myers Squibb Announces Cash Tender Offer For Any and All of Certain of Its Outstanding Debt Securities
Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has commenced a cash tender offer for any and all of its 5.875% Notes due 2036, 6.125% Notes due 2038 and 6.875% Debentures due 2097 (collectively, the “notes”). The tender offer is being made pursuant to an Offer to Purchase dated today and a related... More...>>
06/14/20176:59AMBWBristol-Myers Squibb To Present New Research Related to the Treatment of Rheumatoid Arthritis Patients With Highly Active, Pr...
Key analyses focus on treatment outcomes among RA patients with a traditionally poor prognosis ORENCIA® (abatacept) continuing research underscores Bristol-Myers Squibb’s commitment to advancing the science of modulating the body’s immune response to treat disease Bristol-Myers Squibb Company (NYSE:BMY) today confirmed... More...>>
06/13/20174:05PMBWBristol-Myers Squibb Announces Dividend
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-nine cents ($0.39) per share on the $.10 par value Common Stock of the corporation. The next quarterly dividend will be payable on August 1, 2017, to stockholders of record at the close of business on July 7... More...>>
06/12/201710:00AMBWBristol-Myers Squibb to Announce Results for Second Quarter 2017 on July 27
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the second quarter of 2017 on Thursday, July 27, 2017. During a conference call at 10:30 a.m. EDT on July 27, company executives will review financial information and will address inquiries from investors and analysts. Investors and the general public are... More...>>
06/08/20177:30AMBWBristol-Myers Squibb Announces Availability of New ORENCIA® (abatacept) Subcutaneous Administration Option for Patients 2 Ye...
New prefilled syringe option can be administered at home Bristol-Myers Squibb Company (NYSE:BMY) announced today the availability of a new FDA-approved subcutaneous (SC) ORENCIA administration option for use in patients 2 years of age and older with moderately to severely active polyarticular Juvenile Idiopathic Arthritis... More...>>
06/07/20172:45PMBWLes données provenant de l'essai clinique portant sur la combinaison d'Epacadostat et d' Opdivo® (nivolumab) démontrent de...
Ces données ont soutenu le fait de faire avancer le programme de développement clinique pour epacadostat et Opdivo dans le traitement de ces types de cancers La combinaison de l'inhibition de l'enzyme IDO1 plus Opdivo était généralement bien tolérée chez les patients atteints de certaines tumeurs solides avancées... More...>>
06/07/20176:59AMBWBristol-Myers Squibb to Take Part in Goldman Sachs 38th Annual Global Healthcare Conference
Bristol-Myers Squibb Company (NYSE:BMY) will take part in Goldman Sachs 38th Annual Global Healthcare Conference on Wednesday, June 14, 2017, in Rancho Palos Verdes, CA. Thomas Lynch, chief scientific officer, will answer questions about the company at 1 p.m. ET (10 a.m. PT). Investors and the general public are invited... More...>>
06/06/201710:20PMBWDaten aus klinischen Studien zu einer Kombination aus Epacadostat und Opdivo® (Nivolumab) belegen langlebige klinische Reakt...
Diese Daten unterstützen eine Fortsetzung des klinischen Entwicklungsprogramms für Epacadostat und Opdivo bei diesen Krebsarten. Die Kombination von IDO1-Enzymhemmung plus Opdivo wurde von Patienten mit ausgewählten fortgeschrittenen soliden Tumoren allgemein gut vertragen. Incyte Corporation (Nasdaq:INCY) und Bristol-Myers... More...>>
06/05/20174:05PMBWBristol-Myers Squibb Announces New Collaboration to Evaluate Combination Therapy in Colorectal Cancer
Phase 1/2 study to evaluate the combination of Opdivo® (nivolumab) and Opdivo +Yervoy® (ipilimumab) regimen with Mekinist® (trametinib) in patients with colorectal cancer Bristol-Myers Squibb Company (NYSE:BMY) announced today it has entered into a clinical research collaboration with Novartis to investigate the safety... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V:us D:20170627 20:52:30